Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of...
Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands
Neoadjuvant ipilimumab and nivolumab  immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )
6 Jun 2022
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer P...
Dr Pamela Kunz - Yale Cancer Center, New Haven, USA
Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )
6 Jun 2022
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal strom...
Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain
ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
6 Jun 2022
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-ty...
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Chiara Cremolini - University of Pisa, Pisa, Italy
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
Comment: Dabrafenib plus trametinib significantly increases overall response rat...
Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA
Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )
6 Jun 2022
Dabrafenib plus trametinib significantly increases overall response rate in paed...
Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada
Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )
6 Jun 2022
ASCO 2022: Latest developments in mHSPC and mCRPC
Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller
ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )
6 Jun 2022
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre,  Manhattan, USA )
5 Jun 2022
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...
Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )
5 Jun 2022